172 related articles for article (PubMed ID: 15816854)
21. Selective neuronal degeneration in Huntington's disease.
Cowan CM; Raymond LA
Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
[TBL] [Abstract][Full Text] [Related]
22. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
Wade A; Jacobs P; Morton AJ
Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
[TBL] [Abstract][Full Text] [Related]
23. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
Glynn D; Reim K; Brose N; Morton AJ
Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
[TBL] [Abstract][Full Text] [Related]
24. Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice.
Petersén A; Stewénius Y; Björkqvist M; Gisselsson D
BMC Cell Biol; 2005 Sep; 6():34. PubMed ID: 16159402
[TBL] [Abstract][Full Text] [Related]
25. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
Hannan AJ
Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
[TBL] [Abstract][Full Text] [Related]
26. Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation.
Hernández-Espinosa D; Morton AJ
Brain Res Bull; 2006 May; 69(6):669-79. PubMed ID: 16716837
[TBL] [Abstract][Full Text] [Related]
27. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.
Gianfriddo M; Melani A; Turchi D; Giovannini MG; Pedata F
Neurobiol Dis; 2004 Oct; 17(1):77-88. PubMed ID: 15350968
[TBL] [Abstract][Full Text] [Related]
28. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.
Hsiao HY; Chen YC; Chen HM; Tu PH; Chern Y
Hum Mol Genet; 2013 May; 22(9):1826-42. PubMed ID: 23372043
[TBL] [Abstract][Full Text] [Related]
29. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
[TBL] [Abstract][Full Text] [Related]
30. A new drug design targeting the adenosinergic system for Huntington's disease.
Huang NK; Lin JH; Lin JT; Lin CI; Liu EM; Lin CJ; Chen WP; Shen YC; Chen HM; Chen JB; Lai HL; Yang CW; Chiang MC; Wu YS; Chang C; Chen JF; Fang JM; Lin YL; Chern Y
PLoS One; 2011; 6(6):e20934. PubMed ID: 21713039
[TBL] [Abstract][Full Text] [Related]
31. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice.
Bolivar VJ; Manley K; Messer A
Brain Res; 2004 Apr; 1005(1-2):29-35. PubMed ID: 15044061
[TBL] [Abstract][Full Text] [Related]
32. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.
Vamos E; Voros K; Vecsei L; Klivenyi P
Biomed Pharmacother; 2010 Apr; 64(4):282-6. PubMed ID: 19932584
[TBL] [Abstract][Full Text] [Related]
34. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
35. Essential fatty acids in Huntington's disease.
Das UN; Vaddadi KS
Nutrition; 2004 Oct; 20(10):942-7. PubMed ID: 15474886
[TBL] [Abstract][Full Text] [Related]
36. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
37. Depletion of p62 reduces nuclear inclusions and paradoxically ameliorates disease phenotypes in Huntington's model mice.
Kurosawa M; Matsumoto G; Kino Y; Okuno M; Kurosawa-Yamada M; Washizu C; Taniguchi H; Nakaso K; Yanagawa T; Warabi E; Shimogori T; Sakurai T; Hattori N; Nukina N
Hum Mol Genet; 2015 Feb; 24(4):1092-105. PubMed ID: 25305080
[TBL] [Abstract][Full Text] [Related]
38. Monitoring aggregate formation in organotypic slice cultures from transgenic mice.
Smith DL; Bates GP
Methods Mol Biol; 2004; 277():161-71. PubMed ID: 15201455
[TBL] [Abstract][Full Text] [Related]
39. Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
Kao YH; Lin MS; Chen CM; Wu YR; Chen HM; Lai HL; Chern Y; Lin CJ
Hum Mol Genet; 2017 Feb; 26(3):467-478. PubMed ID: 28069792
[TBL] [Abstract][Full Text] [Related]
40. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
Chiang MC; Chern Y; Huang RN
Neurobiol Dis; 2012 Jan; 45(1):322-8. PubMed ID: 21907283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
